SUBSTITUTED PHENYLALKYLAMINES
Provided are phenylalkylamines, such as 2,5-disubstituted and 2,4,5-trisubstituted phenylalkylamines. In some embodiments, the phenylalkylamines are asymmetrically substituted. In some embodiments, such compounds modulate the activity of monoamine receptors and/or monoamine transporters. Also provided are methods for the preparation of phenylalkylamines and pharmaceutical compositions thereof. Methods of using the phenylalkylamines, alone or in combination with other therapeutic agents, are provided. In some embodiments, phenylalkylamines are used to treat CNS disorders, such as mental health conditions and neurodegenerative disorders, or are used for the improvement of mental health or functioning.
1 - 82 . (canceled)
83 . A compound of Formula (B):
or an enantiomer or enantiomerically enriched mixture thereof, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate of any of the foregoing, wherein:
X is —CH 3 , —CD 3 , —CF 3 , or halogen;
R 1 is —CH 3 , —CD 3 , or —CF 3 ; and
R 2 is —CH 3 , —CD 3 , or —CF 3 ;
provided that when both R 1 and R 2 are —CH 3 , X is —CD 3 or —CF 3 .
84 . The compound of claim 83 , having the structure of Formula (B-1), (B-2), or (B-3):
85 . The compound of claim 83 , having the structure of Formula (B-4), (B-5), or (B-6):
86 . The compound of claim 83 , having the structure of Formula (B-7), (B-8), or (B-9):
87 . The compound of claim 84 , having the structure of:
88 . The compound of claim 84 , having the structure of:
89 . The compound of claim 84 , having the structure of:
90 . The compound of claim 85 , having the structure of:
91 . The compound of claim 85 , having the structure of:
92 . The compound of claim 85 , having the structure of:
93 . The compound of claim 86 , having the structure of:
94 . The compound of claim 86 , having the structure of:
95 . The compound of claim 86 , having the structure of:
96 . The compound of claim 83 , wherein the compound is an (R)-enantiomer.
97 . A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 83 , and a pharmaceutically acceptable carrier, diluent, or excipient.
98 . The pharmaceutical composition of claim 97 , wherein the composition is in a unit dosage form.
99 . The pharmaceutical composition of claim 98 , wherein the unit dosage form is an immediate release formulation, a modified release formulation, a controlled release formulation, an extended release formulation, a sustained release formulation, or a delayed release formulation.
100 . The pharmaceutical composition of claim 97 , wherein the composition is formulated for oral, buccal, sublingual, inhalation, intranasal, injectable, or transdermal administration.
101 . The pharmaceutical composition of claim 98 , wherein the injectable administration is subcutaneous, intramuscular, or intravenous administration.
102 . A method of treating a medical condition in a subject in need of such treatment, comprising administering the pharmaceutical composition of claim 97 .